Anti-tumour necrosis factor therapy modulates the OPG/OPGL system in rheumatoid arthritis synovium

被引：0
|
作者：
AI Catrina
S Ernestam
E af Klint
L Klareskog
AK Ulfgren
机构：
[1] Karolinska Institutet/Hospital,Rheumatology Department
[2] Huddinge Hospital,Rheumatology Department
来源：
Arthritis Res Ther | / 6卷
关键词：
Rheumatoid Arthritis; Tumour Necrosis Factor; Infliximab; Etanercept; Active Rheumatoid Arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis
    Brown, Rachel A.
    Spina, Domenico
    Butt, Sayqa
    Summers, Gregory D.
    CLINICAL RHEUMATOLOGY, 2012, 31 (03) : 455 - 461
  • [22] AUTOANTIBODIES AND SYSTEMIC LUPUS ERYTHEMATOSUS INDUCED BY ANTI-TUMOUR NECROSIS FACTOR ALPHA THERAPY IN RHEUMATOID ARTHRITIS
    Oliveira, D. Santos
    Martins, A.
    Martins, F. R.
    Pinheiro, F. Oliveira
    Rato, M.
    Fonseca, D.
    Fernandes, B. M.
    Garcia, S.
    Vaz, C.
    Bernardes, M.
    Costa, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 318 - 318
  • [23] Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis
    Rachel A. Brown
    Domenico Spina
    Sayqa Butt
    Gregory D. Summers
    Clinical Rheumatology, 2012, 31 : 455 - 461
  • [24] Experiences and needs for work participation in employees with rheumatoid arthritis treated with anti-tumour necrosis factor therapy
    Van der Meer, Marrit
    Hoving, Jan L.
    Vermeulen, Marjolein I. M.
    Herenius, Marieke M. J.
    Tak, Paul P.
    Sluiter, Judith K.
    Frings-dresen, Monique H. W.
    DISABILITY AND REHABILITATION, 2011, 33 (25-26) : 2587 - 2595
  • [25] Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis
    Popa, C
    Netea, MG
    Radstake, T
    Van der Meer, JWM
    Stalenhoef, AFH
    van Riel, PLCM
    Barerra, P
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) : 303 - 305
  • [26] Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe
    Emery, P.
    Van Vollenhoven, R.
    Ostergaard, M.
    Choy, E.
    Combe, B.
    Graninger, W.
    Krueger, K.
    Matucci-Cerinic, M.
    Navarro, F.
    van Riel, P.
    Settas, L.
    Steinfeld, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) : 456 - 459
  • [27] Anti-tumour necrosis factor alpha therapy normalises fibrinolysis impairment in patients with active rheumatoid arthritis
    Ingegnoli, F.
    Fantini, F.
    Griffini, S.
    Soldi, A.
    Meroni, P. L.
    Cugno, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : 254 - 257
  • [28] Staphylococcus lugdunensis septic arthritis and epidural abscess in a patient with rheumatoid arthritis receiving anti-tumour necrosis factor therapy
    Rose, Anna M.
    Barnett, Joseph
    Morris-Jones, Stephen
    Marks, Daniel J. B.
    RHEUMATOLOGY, 2014, 53 (12) : 2231 - 2231
  • [29] ANTI-TUMOUR NECROSIS FACTOR THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS DOES NOT ATTENUATE CUTANEOUS TUMOUR NECROSIS FACTOR ACTIVITY FOLLOWING A TUBERCULIN SKIN TEST
    Byng-Maddick, Rachel
    Haas, Carolin
    Ehrenstein, Michael
    Noursadeghi, Mahdad
    RHEUMATOLOGY, 2016, 55 : 146 - 146
  • [30] Gene expression profiling of rheumatoid arthritis patients treated with anti-tumour necrosis factor
    Coenen, Marieke J. H.
    Toonen, Erik J. M.
    Batliwalla, Franak
    van Riel, Piet L. C. M.
    Kievit, Wietske
    Veltman, Joris A.
    Eijsbouts, Agnes M. M.
    Gilissen, Christian F. H. A.
    Damle, Aarti
    Scheffer, Hans
    Radstake, Timoth R. D. J.
    Gregersen, Peter K.
    Barrera, Pilar
    Franke, Barbara
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S615 - S616
12345